This report expands on the information provided in the original Roadmap to equip stakeholders with current clinical, cost, and patent information to inform decision-making about the best strategies to expand currently limited access to DTG.
The Roadmap Special Edition Report on Dolutegravir
Learn more about how you can help build a more equitable system for all